← Leaderboards
George K Lewis
University Of Md Biotechnology Institute
$7,695,484
Attributed
$8,607,519
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,305,710 · 9
By mechanism
P01$8,239,279 · 3
R01$4,042,360 · 3
R61$1,046,576 · 1
U01$777,495 · 1
U09$200,000 · 1
Top collaborators
- Krishanu Ray2 shared
- Mohammad Mohseni Sajadi1 shared
Most similar at University Of Md Biotechnology Institute
Same institution · by research overlap
- James T. Stivers$16,239,758
- Louisa P Wu$4,002,246
- William Conrad Reid$1,544,214
- Kevin Donald Ridge$1,970,605
- John Moult$7,469,820
Others in their field
Top investigators on “Vaccine Development”
- Lawrence Corey · Fred Hutchinson Cancer Center$718,120,301
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$554,939,981
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$394,383,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$392,263,550
- Dennis R. Burton · Scripps Research Institute$312,611,400
Research focus
Vaccine DevelopmentAntibodiesEpitopesResponseSpecificityCellsNeutralizing Monoclonal AntibodiesIn VitroPlasmaNeutralizing AntibodyAids VaccinesVector VaccineHiv InfectionsHuman Immunodeficiency Virus 1Hiv-1Hiv Envelope Protein Gp120Monoclonal AntibodiesAntibody FormationInfectionMemory B-LymphocyteElementsEpitope MappingEnv GlycoproteinsLength
Grant awards (25)
Molecular determinants of vaccine-induced antibody durability$777,495
U01 · FY2025 · AI
Detection Assays for Virion Susceptibility to HIV Broadly Neutralizing Antibodies in Plasma and Culture Fluids$523,288
R61 · FY2025 · AI
Epitope-Paratope Characteristics and IgG1 Allostery in Fc-mediated Effector Function$463,676
R01 · FY2025 · AI · contact PI
Detection Assays for Virion Susceptibility to HIV Broadly Neutralizing Antibodies in Plasma and Culture Fluids$523,288
R61 · FY2024 · AI
Project 2- Mechanism of How Vaccine-Elicited CD4+ T Cells Attenuate Antibody Mediated Protection$215,183
P01 · FY2019 · AI · contact PI
Project 2- Mechanism of How Vaccine-Elicited CD4+ T Cells Attenuate Antibody Mediated Protection$244,112
P01 · FY2018 · AI · contact PI
Project 2- Mechanism of How Vaccine-Elicited CD4+ T Cells Attenuate Antibody Mediated Protection$272,924
P01 · FY2017 · AI · contact PI
Project 2- Mechanism of How Vaccine-Elicited CD4+ T Cells Attenuate Antibody Mediated Protection$984,538
P01 · FY2016 · AI · contact PI
Broadly Neutralizing Monoclonal Antibodies Against HIV-1$547,121
R01 · FY2014 · AI · contact PI
Broadly Neutralizing Monoclonal Antibodies Against HIV-1$514,295
R01 · FY2013 · AI · contact PI
Broadly Neutralizing Monoclonal Antibodies Against HIV-1$547,121
R01 · FY2012 · AI · contact PI
Broadly Neutralizing Monoclonal Antibodies Against HIV-1$558,285
R01 · FY2011 · AI · contact PI
Broadly Neutralizing Monoclonal Antibodies Against HIV-1$560,996
R01 · FY2010 · AI · contact PI
Broad Neutralizing Monoclonal Antibodies From HIV Controllers$425,433
R01 · FY2010 · AI · contact PI
Broad Neutralizing Monoclonal Antibodies From HIV Controllers$425,433
R01 · FY2009 · AI · contact PI
NOVEL HIV VACCINES$343,000
P01 · FY2005 · AI
NOVEL HIV VACCINES$956,491
P01 · FY2004 · AI
NOVEL HIV VACCINES$934,250
P01 · FY2003 · AI
NOVEL HIV VACCINES$1,220,773
P01 · FY2002 · AI
VACCINE SAFETY AND IMMUNOGENICITY$274,777
P01 · FY2002 · AI
NOVEL HIV VACCINES$1,419,348
P01 · FY2001 · AI
VACCINE SAFETY AND IMMUNOGENICITY$274,777
P01 · FY2001 · AI
NOVEL HIV VACCINES$824,329
P01 · FY2000 · AI
VACCINE SAFETY AND IMMUNOGENICITY$274,777
P01 · FY2000 · AI
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW$200,000
U09 · FY2000 · AI